Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation

Transplantation

Volumn 91, Issue 5, 2011, Pages

  Chan, Kun Ming ^a   Lee, Ching Sung ^a   Wu, Ting Jung ^a   Lee, Chen Fang ^a   Chen, Tse Ching ^a   Lee, Wei Chen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; COMPLEMENT COMPONENT C4D; LIVER ENZYME;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTERY BLOOD FLOW; BLOOD COMPATIBILITY; BLOOD VESSEL WALL; CLINICAL ARTICLE; CLINICAL FEATURE; DETERIORATION; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; LETTER; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER PARENCHYMA; LIVER TRANSPLANTATION; MALE; PLASMAPHERESIS; PORTAL VEIN BLOOD; PORTAL VEIN OBSTRUCTION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL;

AGED; BLOOD GROUPING AND CROSSMATCHING; BORONIC ACIDS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; INCIDENCE; INFANT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; PROTEASE INHIBITORS; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 79952123619     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318208138c     Document Type: Letter

References (14)

1. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
2. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51.
3. Haga H, Egawa H, Fujimoto Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12: 457.
4. Haga H, Egawa H, Shirase T, et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABOincompatible liver transplantation. Liver Transpl 2004; 10: 16.
5. Rostron A, Carter V, Mutunga M, et al. A case of acute humoral rejection in liver transplantation: Successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005; 18: 1298.
6. Kamar N, Lavayssiere L, Muscari F, et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15: 3426.
7. Watson R, Kozlowski T, Nickeleit V, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022.
8. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277.
9. Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 1490.
10. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
11. White NB, Greenstein SM, Cantafio AW, et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004; 78: 772.
12. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
13. Everly MJ, Everly JJ, Susskind B, et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 2009; 41: 105.
14. Wang X, Luo H, Chen H, et al. Role of proteasomes in T cell activation and proliferation. J Immunol 1998; 160: 788.